secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-040981
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo Q2 net loss $7.9M; APVO436 DOR data positive; $5M raise extends cash into 3Q24
--------------------------------------------------------------------------------

- Net loss $7.9M ($1.23/share) vs net income $28.0M in Q2 2022 (which included $37.2M gain); cash $21.0M at June 30.
- Closed $5M public equity raise on Aug 4, 2023; warrants could add $10M; cash runway now into Q3 2024.
- APVO436 + venetoclax + azacitidine in AML: 82% (9/11) response rate for DOR analysis; 3 patients bridged to transplant.
- Phase 2 trials for APVO436 planned: relapsed/refractory in 2H23, frontline in 1H24; ALG.APV-527 Phase 1 interim data in 2H23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017023040981/0000950170-23-040981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017023040981/apvo-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer